Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday

Avalo Therapeutics (NASDAQ:AVTX) will likely be releasing its earnings data on Thursday, March 27th. Analysts expect Avalo Therapeutics to post earnings of ($1.29) per share for the quarter.

Avalo Therapeutics Stock Performance

Shares of AVTX opened at $7.99 on Thursday. Avalo Therapeutics has a 12-month low of $4.36 and a 12-month high of $34.46. The business’s fifty day moving average price is $7.42 and its 200 day moving average price is $9.11.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on AVTX. Piper Sandler began coverage on Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 target price on the stock. Wedbush began coverage on Avalo Therapeutics in a research note on Friday, February 21st. They issued an “outperform” rating and a $18.00 target price on the stock. Finally, BTIG Research began coverage on Avalo Therapeutics in a report on Thursday, December 19th. They set a “buy” rating and a $40.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Avalo Therapeutics has a consensus rating of “Buy” and a consensus price target of $35.33.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.